TRAVERE THERAPEUTICS, INC. Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-21.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2025-02-21
- TRAVERE THERAPEUTICS, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $0.00.
- TRAVERE THERAPEUTICS, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $310.00K.
- TRAVERE THERAPEUTICS, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2021 was $0.00.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-21 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-21 |
| 2022-12-31 | $310.00K 10-K · filed 2025-02-21 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |